Keith Katkin, Director at Syndax Pharmaceuticals Inc (SNDX), sold 7,015 shares at $25.07 ($176K) on 2022-09-30, disclosed to the SEC on 2022-10-04.
Open-market sale of $176k SNDX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.07 | 647 | $16K | 9.2% |
| 2 | $25.07 | 2,914 | $73K | 41.5% |
| 3 | $25.07 | 2,914 | $73K | 41.5% |
| 4 | $25.00 | 13 | $325 | 0.2% |
| 5 | $25.00 | 167 | $4K | 2.4% |
| 6 | $25.00 | 137 |
| $3K |
| 1.9% |
| 7 | $25.00 | 223 | $6K | 3.2% |
| Total | $25.06 avg | 7,015 | $176K | 100% |
| Filing → |
| SNDX | BUY | 2025-05-19 | $91K | — | Filing → |
| SNDX | SELL | 2022-10-07 | $1.5M | — | Filing → |
| UROV | SELL | 2019-12-11 | $1.5M | — | Filing → |